Trophos successfully completes phase 1 clinical trials for novel compound to tre

[Guest guest]

Trophos successfully completes phase 1 clinical trials for novel

compound to treat neurodegenerative diseases

Trials show good patient tolerance, achievement of predicted

effective dose, and an excellent safety profile for TRO19622, one of

a number of proprietary drug candidates being developed for the

treatment of ALS (Lou Gehrig's disease), SMA and other neurological

disorders, including neuropathic pain.

http://www.bioportfolio.com/biotech_news/Trophos_1.htm

Marseille, January 31, 2006 - Trophos, a biopharmaceutical company

specialising in the discovery and development of drugs for

neurodegenerative diseases, announced today the successful completion

of Phase I clinical trials for its lead compound TRO19622.

TRO19622 is representative of a class of novel compounds identified

using the proprietary neuronal cell screening platform developed at

Trophos. In preclinical studies, these compounds have been

demonstrated to promote the survival of a wide range of neurons in

vitro, as well as in several in vivo models of neurodegenerative

diseases. The clinical trials were conducted in France and involved

single and multiple dose studies on healthy adult subjects. TRO19622

was demonstrated to: i) be well tolerated; ii) have achieved the

effective clinical dose via the oral route and, iii) have an

excellent safety profile.

The successful completion of Phase I means that Trophos now expects

to initiate a pivotal Phase II/III clinical trial for the ALS

indication in Q4 2006. The trial will be conducted in the USA and

Europe. TRO19622 has already been granted orphan drug designation

status for the treatment of Amyotrophic Lateral Sclerosis (ALS) in

the USA, and for the treatment of Spinal Muscular Atrophy (SMA) in

the EU.

" We are excited that TRO19622, the lead molecule discovered using our

innovative phenotypic screening platform, has successfully completed

these Phase I clinical studies, " said Dr Pruss, Chief

Scientific Officer at Trophos. " This will allow us to proceed into

clinical trials of efficacy in ALS patients. Our understanding of the

mechanism of action of this class of molecules leads us to believe

they have tremendous potential for the treatment of other chronic

neurological disorders, including neuropathic pain and Alzheimer's

disease. "